Managing antidepressant drug therapy in an evolving marketplace

American Journal of Managed Care

Volumn 10, Issue SUPPL. 4, 2004, Pages

  McCombs, Jeffrey ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

COMORBIDITY; COST OF ILLNESS; DEPRESSION; DRUG EFFICACY; DRUG FORMULARY; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MANAGED CARE; MARKET; MEDICARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DELIVERY OF HEALTH CARE; DEPRESSION; HUMANS; INFORMATION SERVICES; MANAGED CARE PROGRAMS; QUALITY OF HEALTH CARE; UNITED STATES;

EID: 3242767652     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Epstein AM. Rolling down the runway: the challenges ahead for quality report cards. JAMA. 1998;279:1691-1696.
2. Thompson JW, Bost J, Ahmed F, Ingalls CE, Sennett C. The NCQA's quality compass: evaluating managed care in the United States. Health Aff (Millwood). 1998;17: 152-158.
3. Lipton HL, Lee PR. Drugs and the Elderly. Stanford, Calif: Stanford University Press; 1998:85-117.
4. CalPERS Health Plan Decision Guide: Survey Results. California Public Employees' Retirement System, Health Program Development. Sacramento, Calif; 1995.
5. Chernew M, Scanlon DP. Health plan report cards and insurance choice. Inquiry. 1998;35:9-22.
6. Spranca M, Kanouse DE, Elliott M, Short PF, Farley DO, Hays RD. Do consumer reports of health plan quality affect health plan selection? Health Serv Res. 2000;35:933-947.
7. Schultz J, Thiede Call K, Feldman R, Christianson J. Do employees use report cards to assess health care provider systems? Health Serv Res. 2001;36:509-530.
8. Beaulieu ND. Quality information and consumer health plan choices. J Health Econ. 2002;21:43-63.
9. Farley DO, Short PF, Elliot MN, Kanouse DE, Brown JA, Hays RD. Effects of CAHPS health plan performance information on plan choices by New Jersey Medicaid beneficiaries. Health Serv Res. 2002;37:985-1007.
10. McCormack LA, Garfinkel SA, Hibbard JH, Norton EC, Bayen UJ. Health plan decision making with new Medicare information materials. Health Serv Res. 2001;36:531-554.
11. Hibbard JH, Jewett JJ, Engelmann S, Tusler M. Can Medicare beneficiaries make informed choices? Health Aff (Millwood). 1998;17:181-193.
12. McCombs JS, Nichol MB, Stimmel GL. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program. Value in Health. 1999;2:269-280.
13. Hylan TR, Crown WH, Meneades L, et al. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord. 1998;47:71-79.
14. McCombs JS, Shi L, Croghan TW, Stimmel GL. Access to drug therapy and substitution between alternative antidepressants following an expansion of the California Medicaid formulary. Health Policy. 2003;65:301-311.
15. McCombs JS, Shi L, Stimmel GL, Croghan TW. A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. Clin Ther. 2002;24:1939-1959.
16. Katon W, Von Korff M, Lin E, et al. Distressed high utilizers of medical care. DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry. 1990;12:355-362.
17. Russell JM, Berndt ER, Miceli R, Colucci S, Grudzinski AN. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. Am J Manag Care. 1999;5:597-606.
18. Lee LF. Generalized models with selectivity. Econometrica. 1983;51:507-512.
19. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther. 1994;16:715-730.
20. Skaer TL, Sclar DA, Robison LM, et al. Economic valuation of amitriptyline, desipramine, nortriptyline and sertraline in the management of patients with depression. Curr Ther Res. 1995;56:556-567.
21. Warrington SJ, Padgham C, Lader M. The cardiovascular effects of antidepressants. Psychol Med. (Monograph Supplement 16); Cambridge, Mass: Cambridge University Press; 1989.
22. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol. 1997;11(suppl 4):S33-S37.
23. Holm KJ, Spencer CM. Reboxetine: a review of its use in depression. CNS Drugs. 1999;12:65-83.
24. Carlsen A, Waern M, Ekedahl A, Ranstram J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf. 2001;10:525-530.
25. Isacsson G. Suicide prevention - a medical breakthrough? Acta Psychiatry Scandia. 2000;102:113-117.
26. Rihmer Z. Can better recognition and treatment of depression reduce suicide rates? A brief review. Eur Psychiatry. 2001;16:406-409.
27. Hall WD, Mant A, Mitchell BP, Rendle VA, Hickie IB, McManus P. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ. 2003;326:1008-1012.
28. US Food and Drug Administration Web site. Center for Drug Evaluation and Research. Worsening depression and suicidality in patients being treated with antidepressant medications. Available at: http://www.fda.gov/cder/drug/ antidepressants/AntidepressanstPHA.htm. Accessed June 23, 2004.